Clinical trials: Cardiotoxicity
Cardiac Disease, Covid19
Validation of Quantitative Myocardial Tissue Characterization Through Non-gated CT
The main aim is to validate non-gated 5-min computed tomography myocardial relative enhancement (CT-MRE), which can be readily estimated via contrast-enhanced non-gated chest CT, as a tool for estimating myocardial extracellular…
- Conditions
- Cardiac Disease, Covid19, Cardiotoxicity, Extracellular Space Alteration
- Trial name
- NCT04880317
- Testing
- Cardiac Magnetic Resonance, Additional CT acquisition, Blood tests
- Where
- Italy
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- IRCCS Policlinico S. Donato
Chemotherapy-induced Cardiotoxicity, Breast Cancer
Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients
This study aims to investigate the possible role of rosuvastatin in protection against cardiotoxicity in HER2 positive breast cancer patients receiving doxorubicin sequential with trastuzumab.
- Trial name
- NCT05338723
- Testing
- Rosuvastatin 20mg
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
Breast Cancer
Evaluation of Radiation Induced Toxicity to the Heart by Multi-detector Computed Tomography (MDCT)
The current study is aimed to evaluate various imaging methods, including multidetector computed tomography (MDCT) as potential surrogates to assess the degree of damage caused to the heart by radiation therapy to the breast, in…
- Trial name
- NCT01018719
- Testing
- MDCT, ECG, Echocardiography
- Volunteers
- 100 people
- Sponsor
- Western Galilee Hospital-Nahariya
Colorectal Cancer
Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine
observational prospective study, designed for patients with colorectal cancer receiving for the first time 5-FU or capecitabine, with or without other chemotherapy combinations.
- Trial name
- NCT02665312
- Where
- 8 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Breast Neoplasms
Breast Cancer Long-term Outcome of Cardiac Dysfunction
The purpose of this study is to assess the prevalence of cardiac dysfunction and (undiagnosed) heart failure in women registered in general practice with a history of breast cancer who received chemotherapy and / or radiotherapy…
- Trial name
- BLOC (NCT01904331)
- Where
- Netherlands
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Anthracycline Induced Cardiotoxicity
Late Anthracycline Induced Cardiotoxicity- Childhood Cancer Survivors
Anthracyclines treat up to 60% of childhood malignancies with remarkable improvements survival rates. Unfortunately anthracyclines are associated with an increased cardiomyopathy risk.
- Trial name
- NCT04852965
- Where
- United Kingdom
- Volunteers
- 103 people
- Sponsor
- Queen's University, Belfast
Anthracycline-induced Cardiac Toxicity, Breast Cancer
Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients
This study, called "ROSUBREAST", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based…
- Conditions
- Anthracycline-induced Cardiac Toxicity, Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Anthracycline-induced Cardiotoxicity
- Trial name
- ROSUBREAST (NCT07254221)
- Testing
- Rosuvastatin 20 mg/day
- Where
- 7 sites in Iran
- Volunteers
- 400 people
- Sponsor
- Shiraz University of Medical Sciences
Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG
Management of patients with lymphoma is based on the administration of a chemotherapy containing anthracyclines (ATC), and allows cure rates of 65% to 80% at 5 years.
- Trial name
- DETECT (NCT04892667)
- Testing
- Intervention
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Aluminum Phosphide Poisoning
Trimetazidine As a Potential Adjuvant Therapy in Acute Aluminum Phosphide Poisoning-induced Cardiotoxicity
The aim of the present study is to evaluate the potential adjuvant therapeutic effect of trimetazidine in treatment of acute AlP poisoning-induced cardiotoxicity.
- Trial name
- NCT04702906
- Testing
- standard treatment, trimetazidine hydrochloride "metacardia" ® 20 mg tablet
- Volunteers
- 40 people
- Sponsor
- Tanta University
Breast Cancer, Neoplasm Metastasis
Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer
This is an open phase II multicentre study evaluating the efficacy and safety of the non pegylated liposomal doxorubicin (Myocet®) and docetaxel (Taxotere®) combination as first-line treatment of patients with metastatic HER2/neu…
- Trial name
- MYOTAX (NCT00377559)
- Testing
- Non pegylated liposomal doxorubicin and docetaxel
- Where
- 10 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells from the toxic effects of chemotherapy.
- Trial name
- NCT00003070
- Testing
- enalapril maleate, quality-of-life assessment
- Where
- 61 sites in United States, Canada and 1 more
- Volunteers
- 13 people
- Sponsor
- Children's Oncology Group
Cardiotoxicity
Cardioprotection Effect of Linagliptin
1. Background and Rationale Breast cancer is one of the most common malignancies affecting women worldwide and represents a major health burden in Egypt.
- Trial name
- Linagliptin (NCT07852546)
- Testing
- Doxorubicin, Empaglifloz 5 mg orally once daily
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Tanta University